Received May 19, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 3 | Y014510 | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
Caller reported AE on behalf of a patient who was administered a third dose of GARDASIL 9 before the recommended interval. Patient was administered dose 1 on 10/25/2024, dose 2 on 12/6/2024, and dose 3 on 2/7/2025. No symptoms reported. No additional; no adverse event; This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender. The patient's medical history, historical drugs, known drug allergies, concurrent conditions, and concomitant therapies were not reported. On 25-Oct-2024, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), Suspension for injection as prophylaxis (dose, lot #, expiration date, anatomical location , and route of administration were not reported). On 06-Dec-2024, the patient was vaccinated with the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), Suspension for injection, as prophylaxis (dose, lot #, expiration date, anatomical location, and route of administration were not reported). On 07-Feb-2025, the was vaccinated with the third dose of Human Papillomavirus 9-valent Vaccine (GARDASIL 9), Recombinant Suspension for injection (lot #Y014510, expiration date: was reported as 20-Sep-2025, but upon validation it was found to be 01-Nov-2026) 0.5 mL (0.5ml/dose). Per reporter, the patient received this last dose before the recommended interval (Inappropriate schedule of vaccine administered). No symptoms reported. Lot # is being requested and will be submitted if received.